

August 24, 2021

Dear editor,

Please find attached files of revised manuscript in word format

**Title: Value of Teicoplanin Combined with Conventional Vancomycin Therapy for the Treatment of Pulmonary MRSA and MRSE Infections**

**Author:** Wu Wei, Liu Min, Geng Jiajing, Wang Mei

**Name of Journal:** World Journal of Clinical Cases

**Manuscript NO:** 69640

First of all, thank you for your careful guidance of this article. Revision has been made according to the suggestions of the reviewer:

**Reviewer: 06135281**

Pulmonary infections are typically resistant to treatment with cefradine, oxacillin, or methicillin. Teicoplanin is a novel glycopeptide antibacterial preparation for use in place of vancomycin. This novel drug has enhanced antibacterial activity against MRSA and MRSE due to the addition of fatty acid side chains to its chemical structure, which also increases its molecular mass and half-life, relative to vancomycin. In this study, the authors explored the value of teicoplanin combined with conventional (vancomycin only) anti-infective therapy for the treatment of methicillin-resistant MRSA and MRSE pulmonary infections. The study is overall very well designed and the results are very interesting. The reviewer suggests to accept this study after a minor revision. 1. Some minor language polishing should be revised. 2. A short background should be added to the abstract. 3. Tables should revised and edited, some Chinese characters should be replaced.

After receiving the comments, we read the article carefully and found some small loopholes in the language of the article and made modifications. I added a background section to the abstract. Edited the chart.

According to the suggestion, we changed the relavant description.

Thank you again for publishing our manuscript in the World Journal of Clinical Cases.

Sincerely Yours,

Wang Mei